Neumora Therapeutics, Inc.
NMRA Nasdaq
SEC CIK 1885522
Follow Neumora Therapeutics
Weekly email: filings, results
Net income
−$34.4M
+39.3% vs same quarter last year
EPS, diluted
−$0.18
+48.6% vs same quarter last year
Operating cash flow
−$33.4M
+28.3% vs same quarter last year
Operating income
−$33.4M
+42.1% vs same quarter last year
Source: SEC XBRL filings · latest filing